0001193125-13-426319.txt : 20131105 0001193125-13-426319.hdr.sgml : 20131105 20131105061624 ACCESSION NUMBER: 0001193125-13-426319 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20131105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20131105 DATE AS OF CHANGE: 20131105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BECTON DICKINSON & CO CENTRAL INDEX KEY: 0000010795 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 220760120 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-04802 FILM NUMBER: 131190799 BUSINESS ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKES STATE: NJ ZIP: 07417-1880 BUSINESS PHONE: 2018476800 MAIL ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKE STATE: NJ ZIP: 07417 8-K 1 d621183d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 5, 2013

BECTON, DICKINSON AND COMPANY

 

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

 

(State or Other Jurisdiction of Incorporation)

 

001-4802   22-0760120
(Commission File Number)   (IRS Employer Identification No.)
1 Becton Drive, Franklin Lakes, New Jersey   07417-1880
(Address of Principal Executive Offices)   (Zip Code)

(201) 847-6800

 

(Registrant’s Telephone Number, Including Area Code)

N/A

 

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On November 5, 2013, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its fourth fiscal quarter and fiscal year ending September 30, 2013. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”), as follows:

 

  •   Revenues. We present international and total revenue growth rates (for the total company and each of its segments and units, and for our safety-engineered devices) after eliminating the effect of foreign currency translation. We believe that these measures of revenue growth allow investors to better understand the underlying operating results of BD and facilitate comparisons to prior periods.

 

  •   Earnings Per Share from Continuing Operations. We present diluted earnings per share from continuing operations (“EPS”) for the fourth quarter of fiscal year 2013 after eliminating (i) a charge relating to the verdict in BD’s litigation with Retractable Technologies, Inc., and (ii) a charge relating to non-cash pension settlements. We also present EPS for the 2013 fiscal year after eliminating the foregoing fourth quarter charges and the third quarter charge relating to an antitrust class action settlement. We also present EPS for the fourth quarter of fiscal year 2012 and for the full 2012 fiscal year after eliminating a charge resulting from primarily non-cash pension settlements. In each instance, we adjust for these charges because they are not considered by management to be part of our ordinary operations and adjusting for these charges allows investors to better understand our underlying results.

We also show EPS for the fourth quarter and 2013 fiscal year, as adjusted above, after further eliminating the impact of the medical device excise tax that went into effect in January 2013 under the U.S. healthcare reform law. We believe adjusting for the impact of the medical device excise tax facilitates comparisons to prior periods as this tax was not in effect for those prior periods. We also present EPS growth rates for the fourth quarter and 2013 fiscal year after further adjusting for the impact of foreign currency translation during these periods. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD and facilitates comparisons to prior periods.

We also present estimated EPS guidance for fiscal year 2014 after adjusting for the anticipated impact of foreign currency translation and the one quarter of incremental impact from the medical device excise tax that BD will have in fiscal year 2014 compared to fiscal year 2013. Management believes eliminating the effects of foreign currency translation and the incremental impact of the excise tax allows investors to better understand our guidance in relation to fiscal year 2013 and the anticipated underlying performance of BD.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods and to the performance of peer companies. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1    Press release dated November 5, 2013, which is furnished pursuant to Item 2.02

SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BECTON, DICKINSON AND COMPANY  
  (Registrant)  
  By:  

/s/ Gary DeFazio

  
    Gary DeFazio  
    Vice President and Corporate Secretary  

Date: November 5, 2013

Exhibit Index

 

99.1      Press release dated November 5, 2013, which is furnished pursuant to Item 2.02
 EX-99.1 2 d621183dex991.htm EX-99.1 EX-99.1

1 Becton Drive

Franklin Lakes, NJ 07417

www.bd.com

 

 

  LOGO

Contact:

Monique N. Dolecki, Investor Relations – 201-847-5453

Alyssa J. Zeff, Corporate Communications – 201-847-4358

BD ANNOUNCES RESULTS FOR 2013 FOURTH FISCAL QUARTER AND FULL YEAR;

PROVIDES FISCAL 2014 GUIDANCE

 

  •  

Reports adjusted diluted earnings per share from continuing operations of $5.81 for the full fiscal year, in-line with the Company’s expectations. Reported diluted earnings per share from continuing operations were $4.67.

  •  

Expects full fiscal year 2014 diluted earnings per share from continuing operations to be between $6.16 and $6.22, an increase of 6.0 to 7.0 percent, on an adjusted basis. On a currency-neutral basis the Company expects adjusted earnings per share to grow between 8.5 to 9.5 percent, or 9.0 to 10.0 percent excluding the incremental impact of the medical device tax.

  •  

Announces planned stock repurchases of about $450 million in fiscal year 2014.

Franklin Lakes, NJ (November 5, 2013) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.1 billion for the fourth fiscal quarter ended September 30, 2013, representing an increase of 6.8 percent from the prior-year period, or 7.2 percent on a foreign currency-neutral basis. Revenue growth in the quarter was aided, in part, by some one-time items. For the full fiscal year ended September 30, 2013, BD reported revenues of $8.1 billion, representing an increase of 4.5 percent over the prior-year period or 5.4 percent on a foreign currency-neutral basis.

“We are proud of our accomplishments during fiscal year 2013,” said Vincent A. Forlenza, Chairman, CEO and President. “Our strategy of investing and innovating for growth is succeeding. We exceeded our financial and operating goals this year while continuing to deliver on our long-term commitments. We look forward to fiscal year 2014 with confidence.”

Fourth Quarter Fiscal 2013 Discussion

Diluted earnings per share from continuing operations for the fourth quarter were $0.46, compared with $1.35 in the prior-year period. Current quarter results included a pre-tax charge from the RTI verdict of $341 million, or $1.06 diluted earnings per share from continuing operations, and a charge from non-cash pension settlements of $6 million, or $0.02 diluted earnings per share from continuing operations. Results in the prior-year’s quarter included a charge of $20 million, or $0.07 diluted earnings per share from continuing operations, resulting from primarily non-cash pension settlements. Excluding these items, adjusted diluted earnings per share from continuing operations were $1.54 compared with $1.42 in the prior-year period. Adjusted diluted earnings per share from continuing operations excluding the medical device excise tax, which went into effect in January 2013 under the U.S. healthcare reform law, were $1.58. This represents growth of 11.3 percent, or 12.0 percent on an adjusted foreign currency-neutral basis.

For the full fiscal year ended September 30, 2013, diluted earnings per share from continuing operations were $4.67, compared with $5.30 in the prior-year period. Adjusted diluted earnings per share from continuing operations were $5.81 compared with $5.37 in the prior-year period. This excludes the aforementioned fourth quarter charges as well as the third quarter fiscal year 2013 charge related to the antitrust class action settlement of $22 million, or $0.07 diluted earnings per share from continuing operations. Adjusted diluted earnings per share from continuing operations excluding the medical device excise tax were $5.95. This represents growth of 10.8 percent, or 11.9 percent on an adjusted foreign currency-neutral basis.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.1 billion, representing an increase of 6.8 percent compared with the prior-year period, or 6.7 percent on a foreign currency-neutral basis. The segment’s revenue growth reflects strong sales in the Medical Surgical Systems and Pharmaceutical Systems units. For the twelve-month period ended September 30, 2013, BD Medical revenues increased 5.3 percent, or 6.0 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $680 million, representing an increase of 5.4 percent compared with the prior-year period, or 6.3 percent on a foreign currency-neutral basis. The segment’s growth was driven by solid sales of Preanalytical Systems’ safety-engineered products, and strong sales within the Diagnostic Systems unit partially driven by Kiestra Lab Automation installations. For the twelve-month period ended September 30, 2013, BD Diagnostics revenues increased 4.3 percent, or 5.2 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $300 million, representing an increase of 10.0 percent compared with the prior-year period, or an increase of 11.6 percent on a foreign currency-neutral basis. The segment’s growth was driven by solid instrument placements in Cell Analysis, the reversal of an unfavorable timing of orders in the third quarter in Advanced Bioprocessing, and government funding in Japan. For the twelve-month period ended September 30, 2013, BD Biosciences revenues increased 2.0 percent, or an increase of 3.6 percent on a foreign currency-neutral basis.

Geographic Results

Fourth quarter revenues in the U.S. of $851 million represent an increase of 3.4 percent over the prior-year period. Growth in the U.S. was driven by the Pharmaceutical Systems unit, which benefitted from the acquisition of Safety Syringes and strong orders, partially offset by softness in Women’s Health and Cancer. Revenues outside of the U.S. were $1.2 billion, representing an increase of 9.3 percent compared with the prior-year period, or 10.1 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and strong sales of safety-engineered products.

For the twelve-month period ended September 30, 2013, revenues in the U.S. were $3.4 billion, representing an increase of 2.0 percent compared with the prior-year period. Revenues outside of the U.S. were $4.7 billion, representing an increase of 6.3 percent compared with the prior-year period, or 8.0 percent on a foreign currency-neutral basis.

Fiscal 2014 Outlook for Full Year

The Company estimates that reported and currency-neutral revenues for the full fiscal year 2014 will increase 4.0 to 5.0 percent. The Company expects reported diluted earnings per share from continuing operations for the full fiscal year 2014 to be between $6.16 and $6.22, which represents growth of 6.0 to 7.0 percent over 2013 adjusted diluted earnings per share of $5.81. On a foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 8.5 to 9.5 percent, or 9.0 to 10.0 percent excluding the incremental impact of the medical device tax. The Company plans to repurchase, subject to market conditions, about $450 million of its common stock in 2014.

Conference Call Information

A conference call regarding BD’s fourth quarter results will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, November 5th, 2013. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Tuesday, November 12, 2013, confirmation number 69586788.

Non-GAAP Financial Measures/Financial Tables

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying whole-dollar amounts.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare

institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

***

This press release, including the section entitled “Fiscal 2014 Outlook for Full Year”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures, including “sequestration”, which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers’ ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; the adverse impact of cyber-attacks on our information systems; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

 

     Three Months Ended September 30,  
     2013     2012     % Change  

REVENUES

    $ 2,101      $ 1,967        6.8   

Cost of products sold

      1,014        966        5.0   

Selling and administrative

      877        484        81.2   

Research and development

      133        128        3.8   
  

 

 

    

 

 

    

 

 

  

TOTAL OPERATING COSTS AND EXPENSES

      2,024        1,578        28.3   
  

 

 

    

 

 

    

 

 

  

OPERATING INCOME

      76        389        (80.4 ) 

Interest income

      14        12        16.9   

Interest expense

      (34 )      (35 )      (3.3 ) 

Other income (expense), net

      3        (4 )      NM   
  

 

 

    

 

 

    

 

 

  

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES

      60        362        (83.5 ) 

Income tax (benefit) provision

      (31 )      88        NM   
  

 

 

    

 

 

    

 

 

  

INCOME FROM CONTINUING OPERATIONS

      91        274        (66.8 ) 

INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $1 AND $9, RESPECTIVELY

      —          15        NM   
  

 

 

    

 

 

    

 

 

  

NET INCOME

    $ 91      $ 289        (68.7 ) 
  

 

 

    

 

 

    

 

 

  

EARNINGS PER SHARE

       

Basic:

       

Income from continuing operations

    $ 0.47      $ 1.38        (65.9 ) 

Income from discontinued operations

    $ —        $ 0.07        NM   

Net income

    $ 0.46      $ 1.45        (68.3 ) 

Diluted:

       

Income from continuing operations

    $ 0.46      $ 1.35        (65.9 ) 

Income from discontinued operations

    $ —        $ 0.07        NM   

Net income

    $ 0.46      $ 1.43        (67.8 ) 
  

 

 

    

 

 

    

 

 

  

AVERAGE SHARES OUTSTANDING (in thousands)

       

Basic

      194,697        199,072     

Diluted

      198,628        202,439     
  

 

 

    

 

 

    

 

 

  

NM - Not Meaningful

 

Page 1

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

 

     Twelve Months Ended September 30,  
     2013     2012     % Change  

REVENUES

    $ 8,054      $ 7,708        4.5   

Cost of products sold

      3,883        3,755        3.4   

Selling and administrative

      2,422        1,923        25.9   

Research and development

      494        472        4.8   
  

 

 

    

 

 

    

 

 

  

TOTAL OPERATING COSTS AND EXPENSES

      6,800        6,150        10.6   
  

 

 

    

 

 

    

 

 

  

OPERATING INCOME

      1,254        1,558        (19.5 ) 

Interest income

      40        50        (20.6 ) 

Interest expense

      (138 )      (135 )      2.8   

Other income (expense), net

      9        (1 )      NM   
  

 

 

    

 

 

    

 

 

  

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES

      1,165        1,472        (20.9 ) 

Income tax provision

      236        363        (35.1 ) 
  

 

 

    

 

 

    

 

 

  

INCOME FROM CONTINUING OPERATIONS

      929        1,110        (16.2 ) 

INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $222 AND $31, RESPECTIVELY

      364        60        NM   
  

 

 

    

 

 

    

 

 

  

NET INCOME

    $ 1,293      $ 1,170        10.5   
  

 

 

    

 

 

    

 

 

  

EARNINGS PER SHARE

       

Basic:

       

Income from continuing operations

    $ 4.76      $ 5.40        (11.9 ) 

Income from discontinued operations

    $ 1.86      $ 0.29        NM   

Net income

    $ 6.63      $ 5.69        16.5   

Diluted:

       

Income from continuing operations

    $ 4.67      $ 5.30        (11.9 ) 

Income from discontinued operations

    $ 1.83      $ 0.29        NM   

Net income

    $ 6.49      $ 5.59        16.1   
  

 

 

    

 

 

    

 

 

  

AVERAGE SHARES OUTSTANDING (in thousands)

       

Basic

      195,157        205,460     

Diluted

      199,193        209,181     
  

 

 

    

 

 

    

 

 

  

NM - Not Meaningful

 

Page 2

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY SEGMENT AND GEOGRAPHIC AREA

(Unaudited; Amounts in millions)

 

     Three Months Ended September 30,  
     2013      2012      % Change  

BD MEDICAL

         

United States

    $ 440       $ 422         4.3   

International

      680         627         8.5   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 1,120       $ 1,049         6.8   
  

 

 

     

 

 

     

 

 

  

BD DIAGNOSTICS

         

United States

    $ 319       $ 314         1.6   

International

      361         331         9.0   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 680       $ 645         5.4   
  

 

 

     

 

 

     

 

 

  

BD BIOSCIENCES

         

United States

    $ 92       $ 88         5.0   

International

      208         185         12.3   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 300       $ 273         10.0   
  

 

 

     

 

 

     

 

 

  

TOTAL REVENUES

         

United States

    $ 851       $ 824         3.4   

International

      1,249         1,143         9.3   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 2,101       $ 1,967         6.8   
  

 

 

     

 

 

     

 

 

  

 

Page 3

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY SEGMENT AND GEOGRAPHIC AREA

(Unaudited; Amounts in millions)

 

     Twelve Months Ended September 30,  
     2013      2012      % Change  

BD MEDICAL

         

United States

    $ 1,727       $ 1,685         2.5   

International

      2,579         2,406         7.2   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 4,306       $ 4,091         5.3   
  

 

 

     

 

 

     

 

 

  

BD DIAGNOSTICS

         

United States

    $ 1,272       $ 1,259         1.0   

International

      1,374         1,279         7.4   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 2,646       $ 2,538         4.3   
  

 

 

     

 

 

     

 

 

  

BD BIOSCIENCES

         

United States

    $ 354       $ 343         3.1   

International

      748         736         1.6   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 1,102       $ 1,080         2.0   
  

 

 

     

 

 

     

 

 

  

TOTAL REVENUES

         

United States

    $ 3,353       $ 3,288         2.0   

International

      4,701         4,421         6.3   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 8,054       $ 7,708         4.5   
  

 

 

     

 

 

     

 

 

  

 

Page 4

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended September 30,

(Unaudited; Amounts in millions)

 

     United States  
     2013      2012      % Change  

BD MEDICAL

         

Medical Surgical Systems

    $ 252       $ 251         0.6   

Diabetes Care

      113         113         0.3   

Pharmaceutical Systems

      75         59         27.6   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 440       $ 422         4.3   
  

 

 

     

 

 

     

 

 

  

BD DIAGNOSTICS

         

Preanalytical Systems

    $ 170       $ 165         3.2   

Diagnostic Systems

      149         149         (0.1 ) 
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 319       $ 314         1.6   
  

 

 

     

 

 

     

 

 

  
        
  

 

 

     

 

 

     

 

 

  

BD BIOSCIENCES

    $ 92       $ 88         5.0   
  

 

 

     

 

 

     

 

 

  

TOTAL UNITED STATES

    $ 851       $ 824         3.4   
  

 

 

     

 

 

     

 

 

  

 

Page 5

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

 

     International  
                   % Change  
     2013      2012      Reported      FXN      FX Impact  

BD MEDICAL

               

Medical Surgical Systems

    $ 308       $ 282         9.4         11.1         (1.7 ) 

Diabetes Care

      131         120         8.7         11.2         (2.5 ) 

Pharmaceutical Systems

      241         225         7.3         3.3         4.0   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 680       $ 627         8.5        8.3         0.2   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BD DIAGNOSTICS

               

Preanalytical Systems

    $ 172       $ 163         6.0         6.8         (0.8 ) 

Diagnostic Systems

      189         168         12.0        14.6         (2.6 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 361       $ 331         9.0        10.8         (1.8 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  
              
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BD BIOSCIENCES

    $ 208       $ 185         12.3        14.7         (2.4 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL INTERNATIONAL

    $ 1,249       $ 1,143         9.3        10.1         (0.8 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

 

Page 6

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

 

     Total  
                   % Change  
     2013      2012      Reported      FXN      FX Impact  

BD MEDICAL

               

Medical Surgical Systems

    $ 560       $ 532         5.2         6.2         (1.0 ) 

Diabetes Care

      244         233         4.7         5.9         (1.2 ) 

Pharmaceutical Systems

      316         283         11.5         8.3         3.2   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 1,120       $ 1,049         6.8         6.7         0.1   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BD DIAGNOSTICS

               

Preanalytical Systems

    $ 342       $ 328         4.6         5.0         (0.4 ) 

Diagnostic Systems

      338         318         6.3         7.7         (1.4 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 680       $ 645         5.4         6.3         (0.9 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  
              
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BD BIOSCIENCES

    $ 300       $ 273         10.0         11.6         (1.6 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL REVENUES

    $ 2,101       $ 1,967         6.8         7.2         (0.4 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

 

Page 7

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Twelve Months Ended September 30,

(Unaudited; Amounts in millions)

 

     United States  
     2013      2012      % Change  

BD MEDICAL

         

Medical Surgical Systems

    $ 983       $ 978         0.5   

Diabetes Care

      450         434         3.5   

Pharmaceutical Systems

      294         273         7.9   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 1,727       $ 1,685         2.5   
  

 

 

     

 

 

     

 

 

  

BD DIAGNOSTICS

         

Preanalytical Systems

    $ 666       $ 656         1.5   

Diagnostic Systems

      606         603         0.5   
  

 

 

     

 

 

     

 

 

  

TOTAL

    $ 1,272       $ 1,259         1.0   
  

 

 

     

 

 

     

 

 

  
        
  

 

 

     

 

 

     

 

 

  

BD BIOSCIENCES

    $ 354       $ 343         3.1   
  

 

 

     

 

 

     

 

 

  

TOTAL UNITED STATES

    $ 3,353       $ 3,288         2.0   
  

 

 

     

 

 

     

 

 

  

 

Page 8

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

 

     International  
                   % Change  
     2013      2012      Reported      FXN      FX Impact  

BD MEDICAL

               

Medical Surgical Systems

    $ 1,213       $ 1,127         7.6         9.3         (1.7 ) 

Diabetes Care

      519         477         8.9         11.7         (2.8 ) 

Pharmaceutical Systems

      847         801         5.8         5.6         0.2   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 2,579       $ 2,406         7.2        8.5         (1.3 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BD DIAGNOSTICS

               

Preanalytical Systems

    $ 686       $ 645         6.4         7.9         (1.5 ) 

Diagnostic Systems

      688         634         8.5         11.0         (2.5 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 1,374       $ 1,279         7.4        9.4         (2.0 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  
              
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BD BIOSCIENCES

    $ 748       $ 736         1.6        3.8         (2.2 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL INTERNATIONAL

    $ 4,701       $ 4,421         6.3        8.0         (1.7 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

 

Page 9

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

 

     Total  
                   % Change  
     2013      2012      Reported      FXN      FX Impact  

BD MEDICAL

               

Medical Surgical Systems

    $ 2,196       $ 2,105         4.3         5.2         (0.9 ) 

Diabetes Care

      969         911         6.3         7.8         (1.5 ) 

Pharmaceutical Systems

      1,142         1,074         6.3         6.2         0.1   
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 4,306       $ 4,091         5.3         6.0         (0.7 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BD DIAGNOSTICS

               

Preanalytical Systems

    $ 1,352       $ 1,301         3.9         4.7         (0.8 ) 

Diagnostic Systems

      1,294         1,237         4.6         5.9         (1.3 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 2,646       $ 2,538         4.3         5.2         (0.9 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  
              
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BD BIOSCIENCES

    $ 1,102       $ 1,080         2.0         3.6         (1.6 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL REVENUES

    $ 8,054       $ 7,708         4.5         5.4         (0.9 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

 

Page 10

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

SAFETY REVENUES

(Unaudited; Amounts in millions)

 

     Three Months Ended September 30,  
                   % Change  
     2013      2012      Reported      FXN      FX Impact  

TOTAL SAFETY REVENUES

               

United States

    $ 303       $ 291         4.2         4.2         —     

International

      233         216         7.9         9.5         (1.6 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 536       $ 507         5.7         6.4         (0.7 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BY SEGMENT

               

BD Medical

    $ 269       $ 251         7.3         8.2         (0.9 ) 

BD Diagnostics

      267         256         4.2         4.7         (0.5 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 536       $ 507         5.7         6.4         (0.7 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

 

     Twelve Months Ended September 30,  
                   % Change  
     2013      2012      Reported      FXN      FX Impact  

TOTAL SAFETY REVENUES

               

United States

    $ 1,182       $ 1,149         2.9         2.9         —     

International

      917         834         10.0        11.9         (1.9 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 2,099       $ 1,983         5.9        6.6         (0.7 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

BY SEGMENT

               

BD Medical

    $ 1,045       $ 966         8.1         9.0         (0.9 ) 

BD Diagnostics

      1,054         1,017         3.7        4.4         (0.7 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

TOTAL

    $ 2,099       $ 1,983         5.9        6.6         (0.7 ) 
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  

 

Page 11

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2013 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures

(Unaudited)

 

     Three Months Ended September 30,  
     2013      2012      Growth     Foreign
Currency
Translation		     Foreign
Currency
Neutral
Change		     Growth
%		     Foreign
Currency
Neutral
Growth %		  

Reported Diluted Earnings per Share from Continuing Operations

    $ 0.46       $ 1.35       $ (0.89 )    $ (0.01 )    $ (0.88 )      (65.9 %)      (65.2 %) 
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI ($341 million or $211 million after-tax)

      1.06         0.00              

Non-cash pension settlement charges associated with lump sum benefit payments made primarily from the Company’s U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan’s pension cost in each year. The charges also included settlement losses associated with certain foreign pension plans. ($6 million or $4 million after-tax and $20 million or $13 million after-tax, respectively)

      0.02         0.07              
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted Diluted Earnings per Share from Continuing Operations

    $ 1.54       $ 1.42       $ 0.12      $ (0.01 )    $ 0.13        8.5 %      9.2 % 
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act ($13 million or $8 million after-tax)

      0.04         0.00              
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax

    $ 1.58       $ 1.42       $ 0.16      $ (0.01 )    $ 0.17        11.3 %      12.0 % 
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

 

Page 12

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2013 Year-to-Date Reconciliation of Non-GAAP Financial Measures

(Unaudited)

 

     Twelve Months Ended September 30,  
     2013      2012      Growth     Foreign
Currency
Translation		     Foreign
Currency
Neutral
Change		     Growth
%		     Foreign
Currency
Neutral
Growth %		  

Reported Diluted Earnings per Share from Continuing Operations

    $ 4.67       $ 5.30       $ (0.63 )    $ (0.06 )    $ (0.57 )      (11.9 %)      (10.8 %) 
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases ($22 million or $14 million after-tax)

      0.07         0.00              

Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI ($341 million or $211 million after-tax)

      1.06         0.00              

Non-cash pension settlement charges associated with lump sum benefit payments made primarily from the Company’s U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan’s pension cost in each year. The charges also included settlement losses associated with certain foreign pension plans. ($6 million or $4 million after-tax and $20 million or $13 million after-tax, respectively)

      0.02         0.06              
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted Diluted Earnings per Share from Continuing Operations

    $ 5.81       $ 5.37       $ 0.44      $ (0.06 )    $ 0.50        8.2 %      9.3 % 
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act ($40 million or $26 million after-tax)

      0.13         0.00              
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax

    $ 5.95       $ 5.37       $ 0.58      $ (0.06 )    $ 0.64        10.8 %      11.9 % 
  

 

 

     

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

 

Page 13

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Outlook Reconciliation

 

     Reported
Basis		      FX Impact     FXN Basis

Revenues - Full Year 2014 estimated growth

      4.0% - 5.0%         0.0 %    4.0% - 5.0%
     Full Year
2014		      Full Year
2013		     % Increase
     (estimated)             

Reported Fully Diluted Earnings per Share from Continuing Operations

    $ 6.16 - 6.22       $ 4.67      NM

Pending Litigation Settlement (1)

         0.07     

Verdict Charge (2)

         1.06     

Pension Settlement Charge (3)

         0.02     
  

 

 

     

 

 

    

Adjusted Fully Diluted Earnings per Share from Continuing Operations

    $ 6.16 - 6.22       $ 5.81      6.0% - 7.0%
  

 

 

     

 

 

    

FX Impact

         (2.5%)
       

 

Adjusted FXN Growth

         8.5% - 9.5%

Medical Device Excise Tax Impact (4)

         (0.5%)
       

 

Adjusted FXN Growth (excluding the medical device excise tax)

         9.0% - 10.0%

 

(1) 

Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases.

(2) 

Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI.

(3) 

Represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company’s U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan’s pension cost for the year. The charge also included settlement losses associated with certain foreign pension plans.

(4) 

Represents the incremental impact of the medical device excise tax in first quarter fiscal year 2014 (tax went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act).

NM - Not Meaningful

FXN = Foreign Currency Neutral

 

Page 14

GRAPHIC 3 g621183g50o87.jpg GRAPHIC begin 644 g621183g50o87.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`:@#(`P$1``(1`0,1`?_$`,T```$#!0$!`0`````` M```````'"`L!!08)"@0"`P$!``$%`0$!``````````````8$!0<("0(!`Q`` M``8!`P(#!0,'"`@'`0```0(#!`4&!P`1"!()(3$302(4%0KP8191<3(C-K87 ML3,TM78W=SF!D4+5EE<8>.%#4V,D=689$0`!`P,#`@(&!08*!P@#```!`@,$ M`!$%$@8'(3%!$U%A(C(4"'&!D;$5H4)2W1*;BXY' MBH^TM7@AM(]I:SX)`^FPZU.>/.-MZ\J[D9VGL2`]/S3Q]U`]EM-^KCJS[#;: M?%:B!X"YL*TA\D.[!EZ2QO"Y)XT4Z+@,:S-HFJ(_N]P9?-K/"6J,*1TU9NX$ MJAXN+3FXI8KAH9?U1/L8N^Y1#6D?)?S6;M=VPWN3C>(VSMQV0Y&5(=2'7FWD M@+`4BY;0%MD+05!=[*'=)KIWPQ\@O'L/>1?E[UC069S<*(ORHS\5TZ M%K0^0'72PZ"VZ$:;>R>RA3(^.O*[EYR"Y,8GHUBS_?O@+9:%&\@QA'J,$P^$ M;QSQZJ3X2-;I)>B7T`\-MMM8+XUYDJC. M?O-'&EJG&;'/-LE/DMCFHXS"X$8V=HJU3V;\I?RU;VP,63*VI`8^) MALN>9$*XRP7&D*NDMJ`[GT5M]PAW7Y2`HF,I_EW4&E8:94D99"GV^F-71R.: M[!'39.;G8:XNHHY90KF6,9!)9L)BF],QBD$-;D;'^:J9`P>-R'+45$9K)N+$ M=]@$*+39"%/N,$DZ"X2D*;[A*E!-A7._D[Y!8.6W5F\3\O610D!*WDM`+4ARQ&I*2H&MSM3M]8O==BK;39V,LM:FVB;V)FH=VD M]CWS94O451%=(QB[AY&*.QR&`0,`"`AKC2E84_R3CN*>N8V4OU*C9%FKZ+Q@_M4&S>M%@`!%)RU4VKL0A1!'I!`L:\%Q`-B1]M>3^+.*_P#F7C__`(RKG^\M M>_PO)_\`EG_]6O\`BIYC?Z0^T5]%RMBXYBD)DF@G.8=BE+<:\8QA_(4`D1$1 MU\.,R0[QW_\`5J_BIYC?Z2?M%9JT>M'Z";IBZ;/6RH`9)RT72C?[M>/NI6,S=UIM971:V2VUFONG*1E MF[:;GHN)771*;I,JBB_=-U%4RF\!,4!`!U4LPY8W^D/M%?NWR? MC1VH5%KD.C.5CCL1)O;8!90PB.P`4B<@8YA$?R!KRK&Y%`NMAX#UH4/X*>8@ M_G#[:S1%9%PF55!5-=(X`)%$5"*)F`?(2G()BF`?N'5$H*2;*!!KWW[5^OV^ MWLTI1I2C2E&E*-*4:4HTI2=Y6RC3\,8\M>3[Y(!&5:GQ3B5E'``!W"A4@Z46 M3)`3$%R_?.#%213`=SJ'`/OU'MU[GQ&S-ORMS9USR\9$:*UGN3;LE(Z76LV2 ME/B2!4OV#L;<7)6\(&Q]J,^?GLC(2TTGLD7[K6;'2VA-U+4?=2":Y->$B(Z;)DPC_H$M'HGWD!5ZRKMJ(5'+TG MFGB%D)0AJGGND_.:VX'H.I#9!IGJ.8R;BS&W]-^@S6.IN40%0J/0(](CJX?+ M&,7NYW,\0;B-L;FX>IDGNU+CW4VXB_9025'IW"-)Z58OG5=W#QY"VU\P^T`1 MN#:>3\F2D7`>Q\RR7&7?2VI:0GKT25ZAU%95V^<"V_&/9&,``JPE6LB19(P>'CMYAJ]?+WQUE=J?,>C;N;;*)N+ M^(6>G102V4H6GTI4EP*2?$$>-ZL7S=WQ\ESV]MK/!>(W`[";0+C4VHNA MQUA=NRVE-E"@?1?L:36J\/9W/G<`ROA%DBY95&MY6M,WD*;1(8I8>EEFC.C) M)*C[A'\Z"H-VQ?`=SB8/`HZC>*X:G;_^8+)[1;2I&)BY-]%8ID]T0=2HJ&'8!$Y MA\=QU%?F+W%%SG)4C$X9*4X#$-H@16T^ZEN,-!TV_2>WNM43CG(.A"&'R?/=4>GGQ639>AON\LA*%)[:U6K`/S6[`XY^9J M<]M'C-M.4YQPS!<-Y"+E&;:0CW[50JK9XR>(D7;.4%2[E42614*8H@/B`ZZ@Q94>;&;F1%I M]K@#DXP[D?/7+ZV(,]QV&OXS/I=ODXD)>&&-PAEHJ';IR2%B M2.C"%CE7.Y"J%/Z?7X!X^&NF/#NZFF0!,5$C,J?D!E#"$E2E*2@`)'5A!H1,!%14X)$.H4I-MQ$`'8 M`U84;MV4\0VWDL4I2CT'FL?PU^QCRT^\AS[#5TX[\\^;7$&W(6'`_)#,&/)B M#?@20JRD.(L1Z0;FC,N3%7J0M0L>Q^XBI)CLB]VZ)[IW'^;?VZ$C M*5R/PT\CJ]F:HQ"AAA),9%L96#OU427.9RE`65-!3K0-U"T%C932R.FI'3K^<.MKWJ:XS("CR>_P#'7/=] M5O@'DIEOEKQJFL+X?SAD:N0^";,VG93&%V9[67EPX\E:?<>1Y M:5%.GPOZ37&0X>3315PBZG;2V69K+MWB2]FL*:K5PV4,DY0<$-)=22K=0@E. M`["4P"`ZVX2AD@$(:((N"$(-_01TZW\*C&I8[DWIR<)Q+YQ2T)&6VL\=>6DM M79>-;S,)9("I91>Q4H:PAP@^-C678RYI=P/AG;F[2C<@N2 M^#;/'J@<:?<)>W-6:Y4C@8R+ZGWE,Z$BT,(;'()!*(>&J7([0V+NZ+JF0,=- MCJ']HVELD>L.-FX/KKTW)EQE>PM:2#V-_N-=8_:X^JF=V>U5C!W M.(<:<4TZDI=22""+$$&Q!!Z@@]P:DP(4+CM7MUYK[1I2C2E&E*-*5SQ][[.K MQ%?&7'B,=K-XYT@ID6Y%)ZA$GH(+*1]9CUCE#H5236(NN)!_VBD'V!KGA\[^ M_)*/P_CV"LALI^*D`&VJY*&4GT@66JWITGP%=?\`_P"L'BN,XSF^8)S:5S4+ M&/ADV)1J`@J'C6K'B!S%L/%6ZN%A(A;\2W`Z++*.,9$Z#F+G M8TVR1Y:.8NP4:(S[!$PB0PDZ5R[IGW`?#5;A?E_,\6YDH>:,S:,PA$N(L:FW M4=M0"@4AQ(]U1%B/95[)Z;W?,1\N6'YYVRAH%6.Y!QP*\9DFP4NL.]PRXM%E MEA9`N+W0;+38BMX\1P>PEDFSXGYH\%;=%51XQL<9;E*FDJ<]'L#85@)9($[9 M(YGE-G#,U54%4`W1*J(]1``0$=[(G!VR]P93%\Q\(26XDE$AMXL$GR%@$>:U M8>U',^%$! M$QC6$K0LV64CHHFXK:&MA*C.1H^C2%`KFU=O;]=<. MQ-MM-QFV61=%TZCV`2.PK57_P!,?%'MN8_<9^Y&2+3-><9! MT\?5YG-$;BTE;L^54?&94RKNC*I@FBZ4W6D'153))>\/2/24=7/^6'%GR[8) M6_.0%(S.]W"5--K`TKD'VK,-*OIKJSQ+Q!M?A79L?9>RXZFXK9"WGU#]O+ MD6]N0^ONI2C[J;V0FR4UTE]G3.[[*'&YWCV=>+/)O#,X%:9N7/JF5<5.02%_ M7P!4Y=E`8$%1OON(@!"AKI;\GF^W]T<<*V_D%:I^'=#2;GJ6%C4W]2#J0/&P M%<6__L9XKB[%YG;W?BFTM8O8=+G;NHFMNFMN*Y\UI MH^H).8O:`YK`4QB@?'#(AP*(E`Y/Q1!B)#[?I$W*`[?E`-9;X*'_`,K8WR]H;>`[^&WWZY*];UDBHYWZM## M6$L9\V<%7'&417ZYD'+>(9V7S!#5YNS8$D'5>L"$;5;7+Q[(B2:4K),U5T#+ MF*!W)6X&,)A#?6_7RO9?,Y#9\V+D5N.08LM*6%*N;!:25H23X)-C;L+VJ&;@ M::1*2M'12D]?MZ'Z:ROZ0%G:5>;G*&0C"N?P@VXZ0K6T*@!Q9FEG%Z8*P")Q M_F_C1135,3_:](#>S?5-\UBHHV=C4.?O9GJT>G2&SJ^J]OKKUMW7\4LCW-'7 M[>E2#-I$Q*O8S%,)3%@9V MR8Q^WYPN,8PF'_IEPR&YAW'8M$A2E#\P%#8/NURDY"%M]9>W_J,C_:*K(T'] MS:_NT_=5WY><#.*G.7'$UC3D=B&JW:/E6KA-C9!C&;&[UB052,FA-U>V-D"2 M\3*LCB!TS%4$@F``.4Q=PU^6U=[;FV9D$9'`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`.=_5'WBHLG%.1 MK'AW)>-\O4T6)+?BRW0%\JQI5L#V++/5UP5Y'FDF9C%*Z9>L7]8F(AU!KI5D M\?'R^.?Q4P'X22TIM>DV.E0L;'P-O&H(VXIIP+'OIZC^6M^LI]5+W8I%BZ9M M+'QZAEW2)TDI!CBALY=,C*`)?5;)/)11`RR8&W+U@(`.L'-_+1QBVL+4W.6` M;V+YL?5<)O\`35U.>R!'0H'U5I#RMFC+O+;-SK)_(O,3BSY#R'-1<;9,I9#< MN#PU:BS+E:H+KM&"9OD]0K;=03%:,T]DTBCT@)AWUF/&8C%;7PPQN`B!N!'0 MHH9:`U+5:YL3[RUGIJ4>I-6QQU1,UFU5G>6[%ISD5V`S#!;:BKZ*:3>Y*[^\M9ZJ4.G8)Z"IQBXC,6,/)4% ME74J';ZJW$6O]EK+_9^8_JYSK%,7]Y;_`%T_>*N2NQ^BH3#*/[7Y;_MYDC]X MY?783&?N<3^X:_JIK%Z^ZOI/WFIA3MK?Y?7"[_MFPW^XT-KE+R'_`,=Y?_W% M_P#VBJR/"_QO"_ACA%F))JDG9&UPR+C9T\*0@.'4 M')Q$;.-6JA]NLZ3-^V5.0!\`%4=O/6XGRF9%X2$3Z@#R`Y1]NNC?RX99O(\8,Q$F[L*2ZVH>@*/F)^HZC4'SK91D"H]E)! M'W4Q3MW]KC-_ME"P]A13590[ MF.7:@43.B^B<5`#<-33?O)&'XY7!E4 MD.`[-"PT0%IZV/<_0:11ZES?[7O(.9I2=ARMQ*S_`$M1B_EX>LV5:/2=-'I` M<1N$J6B_4="FY&M M"@>A%Q8U^1^)@OE`*FW1Z_L]1KH.$E`1:M"`902"!">&LK;BW7LWC'" M-NY$MP<W#);Y-#U3'^)HN0,0P('FGCY[:99!-7;I.=)B1'J*'E MUZU[^;'*MHQN(PB5?M5NNOJ'3W0`A)^V]7O;C=W''?S;`?PUWFZTEJ5UIE^H M+_R@>:?^';+]YX367."O^JN(_OS_`%%5;L;5FV5V1*W71?=DJ1! MVKDYL-9;ELPGEH6.Z5)3<*'K!J$1$IM3DXK'G_1)KC4^H2[*N*NW"&-^0O&!Q-L9QB(>EYB_E*-B/0?55W^EEYT7C!_-9'AK+S[QU@_DQ$ MV!W"5=VY55CJEEVM1YI5G-5YL8PIQ_XHCD#M7B:?2FJIT*"'44!U^/S*[*A9 MC9QW:TV!FL>M(4L#JMA9TE*CXZ#90)O87%?<%+6U*^&)NVO[`0*D8K7^RUE_ ML_,_U6_UT_>*F2O=/T5"891_:_+?]O,D?O'+Z["8S]SB?W#7]5-8 MO7W5])^\U,*=M;_+ZX7?]LV&_P!QH;7*7D/_`([R_P#[B_\`[159'A?N;7]V MG[J>SU!^0?\`5]O;J&WJJK@^^L.S]`35^X@\88E^@[GJ9KFS15*=2*;S MQ&=;J:3PI1$45GGP#I4I3;"*8@8/`=;K_*A@WV865W(ZDB.ZIN.V3^<4W6NW MIM=(^FHIN-X%;;`]X7)^ZM>'TL^(Y7(O=2C+TW;*G@\(85OMHF7I2&,@V?6D M&M6A&RJFVQ%G9GJPD`?,J9A]FI]\RN4:Q_&JX)/[:7,:0D>D(NM1^JPO]-4> M":4N?KMT2DG[>E2:6N==3>C2E&E*-*4:4KEV^J,[>\YRDXC5[DUBV!7G,L\2 M',M89:*C6PN)6R8;FDTOQRQ:II%%9TO7#M$I--,H&$4TEM@WUL?\MV^V-L[J M>4#P0 M[A./;I>9@D7A7.,2.%MG%/MKXPB!4V<)944`<*#_--U#C^7 M6U'-VR)&]MB/PX2-67A+^(92.ZBD$+0/6I%[#Q(%1[$ROA9@*O[-70^KU_;7 M45]2WVBK]R]KU/YR\5Z\:^9;Q?4!KN3*#7@3=S&3<3I'4EXBP5,$C&),3]0, MNJ1BI+NMEU71++WNE*_T4KL.I]U M7?O5]S6.5)`DLBZDCJ!XCP/KM31OI9>WQQ$S;B?/'(+/6-JIE7.51RPZQ_(HZI$TD(,INS.GJW6NZ0$P$;"0FP@;4G^93?NZ<1E(6$P M4AV-AG8P>+K2BGSE%12;.)[I0!T`-NMSX53X.%'=;6Z\D*="K6/@/XS3(?J2 M.WCA'!?-3CS7.$.+C(9%Y+52:=V7CKBB,5DE1L49,MXV%MD#56'K'KR%F.Z% M%<.E)H)T#*AT@!MIG\ON_H'H MJFS,%MJ2CX1-E+'5(]/@;5TO=E/M\P?9RX+9(S!RDFX*KY9OL*5U@HH+@2&$'$DX,1,!]W?7CF#?;_`"UO2/B=MH6[ MC&%>1%38ZG5K4-3EO#6;6]"!L9$&-BJ=D6"SU5Z@.P_[>-1[/.OD[9.>/ M-C.?(UG$2C]YFS)81^,JF@19Y+FK"#A.M8UK;%J4IEE'SQB1'I3*'Z:NVW@. MM[=E;,N6IX7.M73Z.P'V5)I M=D?@.MV].`N+\46AD@CEZZ`ME7-"R90%4E[N"2+M6!.J'BHG58P$&!=_(R1] MO#7.OF/?"=][XDY.,3^%,_L8X\/+1<:OZ:KJ^L5-\7$^#B);5[YZGZ3X?56W M36+:N%:9?J"_\H'FG_AVR_>>$UES@K_JKB/[\_U%5;D[1RL:,A3DER`\E*0+E2BGH`/$GP%0B(0W)0I9LD+!_**E>G_=$[=48V M(R!4>W M[%?\53XSH:>[J/M%<67U(O>0X]\Y:_CCB?Q0G!R-CVA7K^(F2_+[Q-GMF2']T;F1\//?8\ MII@D:TH405++IS;Q`>FJ0PV#W)*@5$#^:D$FJ3"M%S((4![*;FI1^U_LM9?_H)G^KG.N;< M7]Y;_73]XJ=J]T_14)EDXAU+EEE-,HG.>_9'*0I0W,8QK)+@!0#VB(Z["8WV M844GL&&OZB:Q>KNKZ3]YJ5$X#=Q7@A0.#'$NL7+ES@*N6&K\=L4Q5BAI;)%> M924-)QE,BFTC'2+)=V1RU>,7*)TU4S%`Q3E$-OJILW./ZFWM^<;*E.1^`+@ARS MS.9JLA6ZQC@7)J&TDSI'*W=V^^K(HQS.+:N!**J37UW*Q`$$]AV-J1[+^73? M.XI:',XT<7APKVUNV\TCQ"&NY41V)L!XU^$K.1&00R?,=\`.WVU'9$0!9KF)_Y>N?G/')3._=S)B8E6K;V/"FVE>#BB?VCOT*(`1_-`/C4TP\ M'X./J7_;+ZGU>@?]O&N@O6#*NU&E*-*4:4HTI7F=LVS]JY8OFS=XR>MUVCQH MZ1(NV=M7*1D5VSE!4IDED%T3B0Y#`)3%$0'PU]2I;:PM!(4""".A!'8@T(!% MCVJ/1[Y?T[]^P/:;QRMX,T60R!QYLKF1LN2L&5EHI(6S#D@\.=Y,2]*AT>IU M/X\<*&.N+5`#.8P=P`ID@*;6]_#'/4+-QF=L;T>2QG6P$,R5G2A\#HD.*[)= M':YZ+'KJ(97$*:)?BB[1[CT?1ZONK&^S]]2U<>(55K_&KFI%6K+V"JL5&"I. M4X4JDEEC%,4V,#=*M6V$?'1=VVNQ"8="`[DD6J9`3V4*4`"HY6^7B+NJ4YN' M:*VHN:,+I8$$3BLW+>(*5"#<2LDS44-T+NT5 MG"8B)04VW#6KN=V#RU`CHPF7@9!V`PHEL!)>;3?OY:DZ@`?0D@>JI`S,QKBR MZTM`<(Z^!/TTG^*-OMF?9W->$;=G"W-%:P;,.8UAD*N$O$LL))/59"K M`GUD%7HKR[/QL:D@L/P17 M$YE;.4VFY`(=Q>FL""XF8$<=)VT.VZT"J;'6.

&W/%O"^#XR95GLNZU(W" M$'4^KV&8Z;>T&RJW6W=9ZVZ``5&LAE'L@H,M@I8]'B?IM]U;V^P7]/I.X+L- M5YO\ZZPU;9<.=FS)DCIYP!ZMM>/E7]Y7Y_8=*NF(Q!:(DRA^TO=(]' MK/K]5=E.WV^_?6I-ORU)*KKU2M7'>APGE3D7VS^4^&<*4Z0O^3KS2F<95:E% M*-TG\P]+8(ETHBW.Z410`Z;9`Y_>,`"!=M]9(XCS6,P'(>-RV7=2QCV7B5K5 MV`T*`O:_<].U4.2:6_#6TV+K(%1SW_\`";N\F2],_!K(IRBF!#%&:J_28!#8 MP"7YAML(:W[_`.=/%G_K,?O^BO\`BJ&_A.0_[L_DKRE["?=HZB]/`R\E-N'2 M/S.I@`#N'B(B_P!@UZ/-O%X%_P`;9O\`JK_BI^$S_P#NC^2GH<>?I>>Z+F*7 MBDLD5K&W&FG+K$"3L-YMC*S3S%GN45A85"JBY=+/`)OZ95C)I";S,`>.HCG_ M`)D.-\2TK\/Y)RJ9N3TLP&00RPB^AM)[GK[RS^EOJL M]R?'^3U5LCL;=9W7IYHV3%9RZAI1NW2*(`95=9BNDDF`CX`)U#``;^W6/XZD MHD-J4;)"P3]1JM/8V[VJ*7N?8R[M[V\7N1C^$F17;"3O-OE&#LLO6DR.64E8 M'[QHN0IY#JZ%4%BF#?;6GZU.6Z?0 M#54S@9JS[>E`^F_W5UM]LKZ?GASVZI:+RFZ(_P"0?)!DB'P^7+JZFXB`.A,N\VV$JB?B&M7.1>=-V[^:5C$Z8&WU'JPT3=?]ZOH5 M_J]$^HU(86(C0SK]]WTGP^@?P]ZWQ;??K"=N]76JZ^THTI1I2C2E&E*-*5\] M.X"`@`@("`AX"`@/L$!#QWU\\;^-*TP\VNP=VX><*/HVL5Q<@T=9BYE7NPQJ2Q#NX7'&/8"G*.D2FW41+//I M"5=(>J7<.H&X].^_CJFR?S9Y)QM2<3B&&W".BG75.6_H@)!M]->V]MM@_M7" M1Z`+?EKHLX1=HC@5V_$TI#CYA"&;WWT02=Y8NR@W3)CL=A`YD[++IG-$`IN/ M45@FU*8!V,`ZP%O+E/>^^B49V8HP;]&&_P!FR/Z"?>_I$U>(N.B0Q^Q0-?I/ M4_R?56R[;_3K'=5U5U]I1I2J;?F#\OG_`.&OGT4JNOM*/M]MM*53;[?F\M*5 M72E4V_EWT^FE5TI5/M^32E&WC]OM[=?+>%*KK[2C2E&E*-*4:4HTI1I2C2E& ME*-*4:4HTI1I2C2E&E*-*5YG+QHR2]=ZY;LT.LB?K.EDFZ7J*'`B9/45.4G6 MH<0`H;[B([!K\W7F6$ZWEI0BX%U$`7/87-NI/:OV8CR)*_*C(6X[8FR4E1L! MI('>U&X[[K:W6D+4VV`5D`D)!-@5$=$@GH";5 M^XG*`"81V*`;B(^```>(C^8`U[OWOV%?C;K8=ZL\!8X&U1B,S6IB.G8EPJY0 M0DHIVB^9*K,W"K1VD1RW.=(RC=TB=,X`.Y3E$!\0U1X_)0,M&$W&/-R(BBH! M;:@I)*24J`()!(4"#Z""#5RRV'RN!G*QN:CO1<@A*2IMU"D+`6D+22E0!`4E M04#X@@CO7W)S\'"JQB$Q+QT6M-/TXJ'2D'C=HI*2:Q#J)1[`BZA#.GBA$S"5 M,FYQ`!V#PU]E9"#"4TB8\TTM]P-MA:DI+BSU"$`GVE&QLD7/2O,+%9/)(?=Q MT=Y]N,T77BVA2PTT"`7'"D'0@$@%2K#J.M7;J_/JLJWT;A]_^K7R]*-]??HI M5GGK%!5:*=3MDEX^"AF7I"[E)5TBQ8-@66(W1]9RX.1)/U5U"D+N(;F,`>W5 M%D,C`Q41<_)O-QX3=M2W%!*$W(`NHV`N2`/6;5<<3B,IG9[>+PL=Z7DG;Z&F MD*6XK2"HZ4I!)LD$FW@":^(^S5Z6E)B$C)J,?S%?^!^>1C1X@N]B?F;8'D=\ MP;)G,JU^.:F!1+K`.L@[AN&O,?*8Z7*>@Q7VG)L?3YJ$J!4WK3J1K2.J=2>J M;]QU%>I>%R\"#'ROR'5H4E#OE*T.>6HBRM"O95:]CT/6KWN'W_;V MZKZME&^EZ4;^.VE*-PTI5E?V2`BY6%@Y*9C6,S8S/20$6Z>((/Y@\:@5R_)& MM5#E5=F9MS@=4"`/04=Q\-4,C)X^)+8@2GFFYLDJ#2%*`6X4#4O0D]5:1U-N MPZUI7F&.U8'=E_HI'BP%3,<=RE`VX@(>&L"_,BX\UQ@XY&25R$Y*"4)!TZU"4W MI1J_-"C9)/87O6T_R<-QGN;669JPU"7A\HEQPI"_+08+VIP(/O%`NH)Z$VL" M*1/)V0LRRW(KB8]ROAQOC2*KU@RU.Q[F,O[*W*3KF.QN[=N(LS1BP8@V'X9O MU%.IU@)O``U"-S[BWI+Y(VE(W=AD8N)&D3W4*1*1(+JDPU*4C2A*=/LBX)N" M?"LF[(VAQO`X=Y`B["W&O-SID/$L.)<@+B!A+F10A+NM:UZO:58I38VZDU^6 M$N4G(/)4]B:YFA9BQ47+=AD(VR4Z/Q9,1<'C*HNC22,+:F62UUSMI\\<=H0' MX'*!%!5$$P*)=>=C; M<6-SIM:O?)W!7$.RL5G]MIDQX>Z=OPVW(\QS*,NO9*6GRR]%7C4I"H_F!:C' M*3J2$@K)"JQ#!M^R]%53BWAC$L[4ZLAE20Y(/[)8[!#C,NHMM4;I..T'-?8_ M%-D7,B?U!`J:@BF._4;P#5FV#N'=\3#[5V3M.1%B#+.9E;KSK?FE"8\ETW:3 MJ2"HWZ`W'B>U2'E':7'D_/[[Y(Y`BSYSF!9VZB-'CO>2EQ4N&PDID+TJ4EL6 MN5)LKI8=Z46/SOD)_::=C;(\;0;G<,<\OZ_B64N9JTF#24AY:I*V.)M,`P46 M7+6;FT:N`07,D<03,`].P&U(V=_9]_+0=M;E:Q\[,XW>+6/7)+`TK0Y'+S;[ M*23Y,E*5:5E)L#>W>H?+XJVA%P62WILU_+8W;N9X[D95J'\2=33S4L1W8KZP ME/Q,-2DZT!0!4+7)TU:F?(;D]_#]_GY]8J)^#*UG^3QFICA"L*%.L3=)8%4B)I"@;TAZ]Q/X4C7(_)QV\OD)Z5`_`XNX%PC##!U/1_ MC/AO,4]JNAX7ND)3I(3[74U7R>'^#_\`-K7$L2'E?\R3=I-9(9%4D:8\TX[X MWR4Q]%G(ZB"E14K6-7L]$U^JW/<@\CS,1N7?.VY<&-@\! M*?C-Q'6/,4^8P3YKCKNL%"E%7[)"1:P&J]ZHMI\1\,X_+MYP,M.W+NR# M%F/SX\CRDQA-+GP[$=C0I+J$)0/B'%*U7)T6TVIX]VRNC4^/K7)<];(FDOY* MHUITC/OH1Y8&R%BLC-B#-NQK3!0CV;?/'[P$VS-(W6JH8H>6^LR9S=B,3QXG MM<=L["1G` MI$!B.V5RPV"B*8XL;V.MEN:).(^7JZCAPF4C-PPZF[@O0)R'Z3%W+OK6/<>^ MMQY_9&[=J;D4Z_\``1\?(:>>B&&\M$B0D%#C!)%DE%T+%B0;$7%;J[/XRV;M M/DG86^]G(9BG*2\M$D1X\X9&.AR+$64N,R0E)NM+EG$'4$J%P;&GG\?"D#E! MR\$"E`QAP?U"```FVQR@`;B`!OX:S9QX/_E+>)'IQG_Z8K6OEU15P;QX"38? MC?\`_15242V7N4%IEN64U3;OCJKUKC7;I%M7H.4JYI-W<&D+4VEHD8JT21I! M`T0R714,D@X0)ZO6;J'P)MJ*SMW\H965NR=A)^/B8S;4M8;:O05/L=QYP;@L?Q_C-R8S,S\WO7'MJD/M2@VB&MZ6N*V[%; M#9#RTJ`4MM9TZ18=54GDQS,S5DJ6LBV)&$I6RTC'U`M#"K,L6S&15[W;KE6D M[.I7YR69+I%JL&!%`:-EBAZJ@F]81Z0Z=1N=S3O;0U8Z$*'M&^OL+5,,;\MW&>R8GQ7)2\HSCT MP8D.28PD,M+2?BG[CS7$$Z4@>6!BX/\'AQ5O-R&/.<=ER&?.4VL%2?+8;]PJ'MJ-S?I:L<3^/N&N*MO8K*;Q8G M;H_S#D9R([T23\.PSCXDGX9+[1"%^=*>/[0(59M``21UO6'4?DCGOD/:,.UF M@3-/Q8SOV`YK(EOD7T$-HDHNU5R\O*:Y2J;=T[:-W\._=-1.!UNKH0V$-S#O MJS87DG?_`")E];N".^619M]4*,"7&@;Z0ZD#V;G2H MD=JDS_&N$VSMC>NU]H.OM[=W%C-IRXR9)!>C(R4T@-/D!.LLJ4;+L-:`#W-9 M;@+DWR%R#:,-69_#3%JH^8G#L;17V.*YBO0>)HAVR=O:Y-QN07"ZC>S,TC-R MMW@J!^M44`R?3MJ\.,).A0!*&^^F8VKA\[EL=FLBA2IN+=<R-" MP+.2E9>.QLWO,T.-HZ3FCK*2*K.K'6,V3:*+.#J$;=0MTU3"8I`'47P?%>`V MYEQD/K"JI2\%B_% M%HS^XMO M1\1YT?:N*:GJ*VY"FY#3\E6M"VUCVC[:E7'N@=""*RAMKYDI\39V[Y6=5'E; MYSS^)0&GHK;L.1%A)\MQMYL^P+-)1I/O%0)!!I?R&0G2GHS;61PH MQ)8:80W'8QX4%)C1FDC2RD$7NGVB2222:NRG&S%2F-I'$XQJY(]`WK)H#-E`X)A[H%]WRU6'C/::MLN;2+3OX*[-5*4GS%:O M.4_\02%]P/-ZV[6Z=JH4\T[]1O1G?X?9_P`R,8Y,%"_*3H^'1&^$"2BUB?(] MDJ[W]KO3(>17&"VY*L>6JS2<'K0Q,LN6*4I?RYD>QV,Y$X),TE+]:L6LDD_F M%PB4$!*DB!3$'L$6_9G* MM'2K%\Q(LDH0?<,&WB'AK/N8V-AMP[1;V?FPMR`VTRD+2HMN)<8"2V\VM)NA M:5)"DD=C6J&W>3]R[/W^]R'MA3;&5>>DJ4A:4NM+:E:P\PZVL%+C2T+*%I(Z MCUTFC3AMA\D=?FDRK=;7(91AZQ!WNQ6BX2LO/S[.H2/S.!!1^X4$6AF;C8`! M$"%$@;;>T8PSPOLX19\>:J=+?RK++@QXL-IEAAH1HX0L.1/PZ-GB;(%C;N>IK&.1]ARDXL\=#Y5RHG,HQ=/O,I$15 MYH+6`BFK6'NL4P.DDLE\Q17`Y-RJ'1'I$W280UA:!PBSEL_N/(;J, M+=*4TEAK$$GZ,-#S3://\.[)%-_U3=8"E712]P#]/@$^S/$^VLIDQEX3L_&3 MOAVV'%09"XX>9:%FVW4H]E7ECV4*L%)3T!M6)]O<\[TPN%5@,DSB\UBA+=EM M(R<1J88\E\W>>94X-22ZKVG$7*%JLHIOUHO_`!4QI?YL+(N_O%7G'U=94^T2 ME+N,O7'=XJT>D*+6'N*S-4#S0)(F,0JYQ!R4AS%`^P[:;@XGVSN*=^)N.3XL MY<9,=]<:2XRJ4P@62W(*3=RPN`LV6`2-5C3:7/6]MI8O\%::Q<[%M3%RXK4R M&U(1"E.&ZGHB5BS-S8EL?LR0DE-Q2.VGA\PG<[4J9ADI.A8RQ]@%7&]-D\?6 M=Y5;)69A6SJ.E63'X']J&Y;AQC(;\A387FX_;&/V M^8<=<1]3#S+GG%6E&GNA39]K5>YZ]^M9%P7S%2\7Q7D\;DE,9;>^7W:,C,;G MQ42HTEH1@D+7KZ!Q+P]D)TD)Z#V>E+O5^,&'J>UQ@T@J^X01Q*>WKU8%Y)V\ M,Y>WUH+.W25C4C)85XL33D MX36H"]T.R$(6GK^DDD&L\?+GM;`;PY#=Q&Y8R)>-3AI-YYI5DI9HL55_' M2B)3'0=K@*BC@PI``;!JFQO(F(@;HEX;(39DEN_$OFK M->.K3!8HOW:RJ*+:M2DI0>G4U:\1\OV\\E"C9B=(QN/P#V(3DG94EXH:BQ772S'5(TM MJ6ER2XD^0TA*UN`:@`*4K%^7JQF.FR-IJ991@K$R4U6I^!GV7RVQ5:U0>Z4G M!SC#U5BMWS)0Q1]TYTSD.4Q3"`ZDVUMXXO>6%^>.\YQSN1G!Y_R'42&69+#["_,CRHK_5M]ARP*D+`( MZA*@04J`(IF7&GF:U?4#'++*#+((3F02T/@FY9( M3Y*G->KHLA"EA!0%G255BR%\N6^)N";R")&,1N-[%*R;.)4^1DGH"4E?Q"&= M!1U;"G$-J<#JFP5!%JR2T\EJ[2;S&5.UT;)$)`S%NC*%'9+?5]LG07%KFA(G M$QQ9`)(TD5O(.#@BFZ%J#<5AZ>KVZN.5Y-QV$SS6(RT#)L8]Z6B*B:II(B%] MRP;1KUZ[+4=*5EO1JZ7JS8+A3,[FVN_N#`93"RLK&Q[LYS&H?49Z8K-RZYY? ME^7J;2"M30=\P(]K3X4SR5Y@9)Q5$9,DGU9LF4%B\O7>*X;X.-2785FI*KUU M`L*"B+QDL:953>J_+4S`8JZYMCF*&L-3.9=R;2AY23)B2LFL;Q5`;TH"DLL$ MLCR[A23YI"E>2""%*-B0*V*@?+OLO?N0PD*+.A8-H\=HRCVMPI2"A/Q"@04(%TI)K,0Y8SU.Y#9SA+!6,JVVN0N-,6WN(H5;JS20EJ%#O(V M6<6^4GR#(-T&K@IRI"=N5=98XIB"93;#J^'EO(X7D+.Q,C#RTO&,XV#);BLL M)6Y&0I"U25O#6D)(]FZ0I2C8A(-JCAX!Q6X^(-JY/$3L#C\S)S>4@NSY,I;; M4]Y#C28C3!\M2E)MJ"7"A"`%`K(N*R#$C688-)B8B M2I*.6"PK$0678.1W*83;%/\`EU8>0MZ2QP[*WOMI3T9]R(T\PI:=+B4N.-V* MDF]B4J[>@U*N(^-X"?F)A<:[V:CSHS$^1&DH;65LK6RR[<)6-)4$N)'46N4U MYBXID;,S9CS9D8V-Y7D)#45Z8R"VKS00I2'U>^I71" MR$CH:_=7#N=W3L_'2MN8S'L.IAYF;Y_Q2S(GQ\?)TNI+"@4(*4B7(R462Q+>M3\F0CS$1V/:`6XEOV MW+E*6T]5*J,[;X$WON3%X_.H7`BX2="E35/R'O+1%A0W`R[+DV2HMM*=/ELZ M0M3J^B4UAZ_-C&J4='H)57(CK(\A>'^.2X<2@V):I*DEP-A( M:LL+\PI4D^S99,JAF;]N114J+MN(]) MR@8P`8!V$=9]!2\ MS(2RXI`=:5J;<"3;6VH@$H5W22!<>`JYZJJHJ-*4:4HTI1I2C2E&E*-*4:4H MTI3=>3V*+'F3&C2GU=U&M)-"^4&S'6E5%2-ACZQ9F$Q()@9(AS_$*-6Q@3#; M83"&^L<\H[1R&]-LHPV,4VB2F?$?NLD)TL/H<6.@/4I2;>NLP\';]PW'&]G- MQ9U#SD)6*GQ@&@"KS),9QELV)`TA2@5>-J06W\4[W/0')D8Z8@&5NO>7X#,F M%Y-11R+>OVBHQL2$"O/="7J$`S]@HFL"75N@J/YM0'*\3YR="W.IAUA&6GYE MG(XY9)LT_'0WY1MK8K+;)$R/+=V]BMNOX?,M`)U/QI M;COGI8N;'V'$J1JM[:16!6'A1<@I&!IQLG4;QE#&LQ=[+D>NSTI,PE9R'+93 M,=U=%6,_&"63B)&/>G)\"L4H@ITI`(J68?YF=MG<^Z\6\Z`!Y:R]Q[M@[=V\[&8UF,CF\9#C,LM/S&6X[@2@E2F MVV6O9;92HG0FY/4D]Z0!IQ\:RU)YSVC)YNSO(BFIOX%D]MR,>TFR?-2Z[C&X22H7MH#J23U MOIMTO2?P7#>?JE\LD1(8JQ;E;'=FRY(9&97"S6NRQ4_7XVPSH6&2BI2HMO4A MYZ2@Y$3&CUR"0A@Z?4#<-1N%PO/Q.?D0WL1BLMMR5EU3!(?D/-NM)==\Y:%Q MTW;=6TNY:4+`]-7:I=E?F.Q.?VK"GQ,]G<#O"%MY&.7$C18SK$AR.Q\.VZU+ M59YAM]NP?0=1'70;&L3G^&V=K%:GAYPE&L[U'D##93:YEL5JLCRTNJ%%6AM+ MQU#C*ET_**ZK"Q:0-BF)U(*%)N``8VX6O(<,;[R>86YD$P)3R=P-SAD79#RI M"HS;R7$141[>6SY:!HZ720.EB;U?\3\QW%F'P+:<6/%CHBIG MNQE,N3G95_.D!YT^80;+238D@6*M6[BWE-UC[+C&O/ZHM;9GE*PY"T=E(.7J M$3(L(61@'[6O3CU)$RT>Y?%C%2"J0IRIB)1\?'4MS'%6Z7=O9AG'.159=_=: M,O&0M2@VM+:VEI9<4!=!7H()`-NAK'^WN=-B1]W;>E9=F>G;\;8CF`FK;2A3 MK;CS;[:I#""=+B4>8DA*B"H:AZ*5JD8>OZ63<\9-LZ-?BULQ8VQ_7FD+'OU9 M(\+.UV"GF$LVAMU-,3R)A29KS;B'Q^A[5!.,O255=X9S/"0*RCMPM M@5^]"S6::5*4H+Q\\X?%"$E&E"E`7+A":VHV=R9C.Y`W*'GXL>2\Z_Y=BXHNMNI)&H@$E:[FY]-(K:. M*M@N#CE"E*R$.DTS!6L6)49RD=8[J$MN-*TU1C95\`IAZ*;:S1Z*I#)B)A1` M?:.VH1D^*,AF'=TIEN-!C,Q8(C$$E3;\)E(0XKITL\A*@1UTWK)6$YXQ&WF= MC*@LR%/[=FY0S4D)TO1,E)47&F^O4JC.+0K58:R/"DFE>%>2YK$6/)*QR--M M>?*YEJ1S3>V3]S+L*/?IN=9*PDO7AE6`HS,6@A!E1(Q_A5)12QQ+D?>20](IFY` M)N.XAKWD^+MS5+ MA.<\)CN08N5G;SW%*V[!@):_:8V,IF2A;WF28*X.L-".ZGLIS40X2NPM3]\3 MUNUT_&E&J]YM"EUN$#6HJ+L=K5(8BD]+-&I$G<@<#^^85E`_2-[Q]NH?$1UL M#M/'97$;9@XO.RC-S#$5M#SY%O-<2D!2_3U/B>I[GK6J&_LS@=Q;URF=VO!& M,V[+G.NQXH-PPTM1*&Q;IT'@.@[#H*4+4AJ(T:4HTI1I2C2E&E*-*4:4HTI1 MI2C2E&E*-*50/(/S!_)I2JZ4H#_3YCY_GTI5`]OGYAY^?Z(>?WZ4JNE*-*4G M2/\`><\_N[_9E#^9_O._I0?TW_\`,?\`I_\`NZC:/^)W/\-_=AV_?>_YW_@^ MCUU+W?\`@AK_`!G]^5[W^&^[^9_^3^E_-I1=22H@.U&E*-*50/(/S!_)I2JZ &4HTI7__9 ` end